CANDEL THERAPEUTICS I

Candel Therapeutics Appoints Seshu Tyagarajan, Ph.D., RAC, as Chief Technical and Development Officer

02 Mar 2022 08:00:02 By Nasdaq GlobeNewswire

Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank

01 Mar 2022 08:00:02 By Nasdaq GlobeNewswire

Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer

03 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics to Present at Two Upcoming Investor Conferences

05 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

Bionaut Labs and Candel Therapeutics Announce Strategic Collaboration in Precision-Targeted Delivery of Oncolytic Viral Immunotherapies

15 Dec 2021 05:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics and Partnership for Accelerating Cancer Therapies (PACT) to Collaborate on Lung Cancer Trial for CAN-2409

10 Dec 2021 08:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

12 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Presents Novel Biomarker Data Demonstrating Immune Activation After Administration of CAN-3110 in Patients with Recurrent High-Grade Glioma

12 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics to Participate in Three Upcoming Investor Conferences

02 Nov 2021 08:00:03 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Upcoming Data Presentations on its Oncolytic Viral Immunotherapies

01 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Patient-Reported Tolerability Data of Intraprostatic Injections in Ongoing Phase 3 Clinical Trial of CAN-2409 in Patients with Localized Prostate Cancer 

28 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Appoints Mace L. Rothenberg, MD, as Senior Advisor to the Chief Executive Officer

19 Oct 2021 08:00:02 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Participation in Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

04 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Participation in Upcoming Scientific Conferences Related to Oncolytic Viral Immunotherapies

01 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Presentations of Key Clinical Data at AdMeTech and European Association of Neuro-Oncology Conferences in September 2021

09 Sep 2021 08:00:03 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights

08 Sep 2021 08:00:03 By Nasdaq GlobeNewswire

Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer

07 Sep 2021 08:00:02 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Closing of Initial Public Offering, Including the Partial Exercise of Underwriters’ Option

17 Aug 2021 08:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Pricing of Initial Public Offering

26 Jul 2021 21:05:38 By Nasdaq GlobeNewswire